Prognosis of signet-ring cell carcinoma after proximal gastrectomy was comparable to total gastrectomy but with better nutrition status

Table 2 Demographics and clinicopathological characteristics of patients with upper gastric signet-ring cell carcinoma who underwent total gastrectomy or proximal gastrectomy after propensity score matching, n (%)

Demographic and clinical characteristics		SRCC
		PG (n = 94)	TG (n = 130)	P value
Sex	Male	52 (55.3)	74 (56.9)	0.939
	Female	42 (44.7)	56 (43.1)
Age, mean (SD)		57.54 (11.82)	52.87 (10.68)	0.115
BMI, mean (SD)		23.71 (3.48)	23.31 (2.96)	0.601
Surgical approach	Laparotomy	48 (51.1)	68 (52.3)	0.338
	Laparoscopy	46 (48.9)	60 (46.2)
	Convert to laparotomy	0 (0.0)	2 (1.5)
Neoadjuvant therapy	No	74 (78.7)	92 (70.8)	0.104
	Yes	20 (21.3)	38 (29.2)
Size, mean (SD)		2.76 (0.82)	2.90 (0.91)	0.118
Lauren	Intestinal	14 (14.9)	15 (11.5)	0.121
	Mixed	24 (25.5)	30 (23.1)
	Diffuse	56 (59.6)	85 (65.4)
Borrmann	Superficial	48 (51.1)	63 (48.4)	0.062
	Ulcerative	46 (48.9)	67 (51.6)
Vessel invasion	Negative	44 (46.8)	74 (56.9)	0.055
	Positive	50 (53.2)	56 (43.1)
Nerve invasion	Negative	40 (42.6)	50 (38.5)	0.061
	Positive	54 (57.4)	80 (61.5)
Pathological T-stage	T3-4	64 (68.1)	92 (70.8)	0.772
	T1-2	30 (31.9)	38 (29.2)
Pathological N-stage	Negative	37 (39.3)	64 (49.2)	0.617
	Positive	57 (60.7)	66 (50.8)
Pathological stage	I	38 (40.2)	46 (35.4)	0.833
	II	20 (21.3)	26 (20.0)
	III	34 (36.3)	54 (41.5)
IV	2 (2.2)	4 (3.1)

SRCC: Signet-ring cell carcinoma; BMI: Body mass index; TG: Total gastrectomy; PG: Partial gastrectomy.